A5037127072- Nanoparticle-Based Drug Delivery
- Alzheimer's disease research and treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Nanoplatforms for cancer theranostics
- RNA Interference and Gene Delivery
- 3D Printing in Biomedical Research
- Immune cells in cancer
- Corneal Surgery and Treatments
- Ocular Surface and Contact Lens
- Lipid Membrane Structure and Behavior
- Prion Diseases and Protein Misfolding
- Advanced Drug Delivery Systems
- Amino Acid Enzymes and Metabolism
- Neurological Disease Mechanisms and Treatments
- Immune Response and Inflammation
- Neonatal Health and Biochemistry
- melanin and skin pigmentation
- Laser-Ablation Synthesis of Nanoparticles
- Hydrogels: synthesis, properties, applications
- Glioma Diagnosis and Treatment
University of Rhode Island
2021-2024
Northeastern University
2024
University of California, San Francisco
2019-2023
Cellular assays reveal a decline in Aβ and tau pathological conformers Alzheimer’s disease brain samples.
Abstract Microglia are central to pathogenesis in many neurological conditions. Drugs targeting colony-stimulating factor-1 receptor (CSF1R) block microglial proliferation preclinical disease models have shown mixed outcomes, thus the therapeutic potential of this approach remains unclear. Here, we show that CSF1R inhibitors given by multiple dosing paradigms Tg2541 tauopathy mouse model cause a sex-independent reduction pathogenic tau and reversion non-microglial gene expression patterns...
Uveal melanoma (UM) is the most common primary intraocular tumor in adults with high mortality. In order to improve prognosis and survival of UM patients, it critical inhibit progression metastasis as early possible after initial presentation/diagnosis disease. Sustained local delivery antitumor therapeutics posterior region can potentially achieve long-term inhibition, target therapeutic segments, well reduce injection frequency hence improved patient compliance. To address highly unmet...
ABSTRACT Glioblastoma is the most aggressive type of brain cancer with an average overall survival 15-21 months after first diagnosis. The relapse mainly caused by migrating glioblastoma cells that diffuse away from tumor mass into parenchyma and retain stem cell (GSC) properties. Current therapeutic options are ineffective inevitably result in relapse, indicating a high unmet medical need for innovative therapies treatment invasive glioblastoma. To address this challenge, we propose new...
ABSTRACT Microglia are central to pathogenesis in many neurological conditions. Drugs targeting colony- stimulating factor-1 receptor (CSF1R) block microglial proliferation preclinical disease models have shown mixed outcomes, thus the therapeutic potential of this approach remains unclear. Here, CSF1R inhibitors were evaluated tauopathy mice using multiple dosing schemes, drug analogs, and longitudinal measurements brain plasma. A sex- independent reduction pathogenic tau was seen several...